Camargo, Marcela Rodrigues de [UNESP]Gorgulho, Carolina Mendonca [UNESP]Rodrigues, Cecilia Pessoa [UNESP]Penitenti, MarcimaraLongo Frederico, Juliana Cristina [UNESP]Marchesan Rodrigues, Maria Aparecida [UNESP]Kaneno, Ramon [UNESP]2018-11-262018-11-262017-10-01Cancer Biotherapy And Radiopharmaceuticals. New Rochelle: Mary Ann Liebert, Inc, v. 32, n. 8, p. 302-308, 2017.1084-9785http://hdl.handle.net/11449/163407Aim: Considering the central role of dendritic cells (DCs) on the development of an antitumor immune response, in this study we used a murine model to evaluate how DC transfection with drug-treated tumor cell RNA changes their phenotype, and whether transfection enhances the in vivo effectiveness of a DC-based antitumor vaccine. Materials and Methods: MC-38 colorectal tumor cells were pretreated with the minimum effective concentration of 5-fluorouracil (5-FU), then their total RNA was extracted and transfected into DCs. These DCs were inoculated into C57Bl/6 mice bearing subcutaneous MC-38 tumor. Results: DC transfection with drug-treated tumor RNA increases the percentages of CD40(+) (from 37.6% to 61.4%), CD86(+) (from 39.8% to 53.4%), and major histocompatibility complex class II+ (from 51.2% to 75.3%) cells, whereas significantly increases the in vivo generation of interferon-c producer lymphocytes. Conclusion: These results reinforce our view that treatment of tumor cells with 5-FU induces transcriptional changes that can be transferred to DCs by RNA transfection, enhancing their ability to stimulate an antitumor response.302-308engchemotherapycolorectal cancerdendritic cellimmunomodulationvaccineArtigo10.1089/cbr.2017.2259WOS:000413337900005Acesso aberto88458355506378090000-0002-4292-3298